Media
View our latest materials to follow our progress in tackling respiratory diseases.
Latest Videos
View all videos
Filters
Verona Pharma plc: TR-1: Standard form for notification of major holdings
LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) -- NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :
Verona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights
LONDON and RALEIGH, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, notifies the following transactions by persons discharging managerial
Verona Pharma Announces August 2020 Virtual Investor Conference Participation
LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, and Mark Hahn, Chief
Verona Pharma plc: TR-1: Standard form for notification of major holdings
LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :
Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update
LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the three and six months ended June
Verona Pharma plc: TR-1: Standard form for notification of major holdings
LONDON and RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :
Verona Pharma
Investor Information
© Verona Pharma plc 2020. All rights reserved